Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
26 hedge funds and large institutions have $11.8M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 6 closing their positions.
21% more capital invested
Capital invested by funds: $9.7M → $11.8M (+$2.06M)
16% less funds holding
Funds holding: 31 → 26 (-5)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$296K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$70.1K |
| 3 |
ACA
Apis Capital Advisors
New York
|
+$49.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$14.8K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$11.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$389K |
| 2 |
BlackRock
New York
|
-$214K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$118K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$42.1K |
| 5 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
-$34.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $3K | -$309 | -25 | -9% |
|
|
27
Citadel Advisors
Miami,
Florida
| – | -$118K | -11,110 | Closed |
|
28
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$21K | -2,025 | Closed |
|
|
MFIM
29
Mesirow Financial Investment Management
Chicago,
Illinois
| – | -$8K | -753 | Closed |
|
|
CAC
30
Certified Advisory Corp
Altamonte Springs,
Florida
| – | -$5K | -500 | Closed |
|
31
Fidelity Investments
Boston,
Massachusetts
| – | -$2K | -200 | Closed |
|
OPNT Hedge Fund Activity: Q2 2021 in Review
26 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q2 2021, worth a combined $11.8M — up 21% from $9.7M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of OPNT and 1 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $296K. The largest seller was Renaissance Technologies, cutting an estimated $389K.
- 26 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q2 2021, down from 31 in Q1 2021.
- Funds reported $11.8M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q2 2021, up 21% quarter-over-quarter.
- 1 fund opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q2 2021 and 6 closed out, a net change of -5 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q2 2021 was Vanguard Group, an estimated $296K added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q2 2021 was Renaissance Technologies, an estimated $389K sold.
Based on aggregated 13F filings for Q2 2021.